Video abstract of review “Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement” published in the open access journal Patient Preference and Adherence by authors Giorgino F, Penfornis A, Pechtner V, et al.
Hello i am professor francesco georgina and on behalf of my co-authors i would like to present an overview of our article in title adherence to anti hypoglycemic medications and lp1 receptor agonist in type 2 diabetes firstly most patients with type 2 diabetes are prescribed anti hypoglycemic medications but adherence is often poor and unrecognized by the prescribing
Physician indeed according to the world health organization adherence to long term therapy for chronic asymptomatic diseases such as type 2 diabetes averages about 50% in developed countries and is likely to be lower in developing countries importantly poor adherence to anti hypoglycemic medications can lead to suboptimal glycemic control as well as increased risk
Of diabetic complications hospitalization and thus inappropriate use of healthcare resources in addition poor adherence may occur regardless of the specific anti hyperglycemic regimen used and apparently with both oral and injectable therapies with this in mind in our comprehensive review we discuss several aspects of adherence to anti hyperglycemic medications these
Include how adherence is defined and measured the extent of poor adherence reasons for poor adherence clinical consequences of poor adherence and strategies to improve adherence notably among those factors that are especially important in increasing adherence to injectable anti hyperglycemic medications improvements in drug administration regimen formulation and
Delivery devices play an important role in fact advances in this area are an important theme in our review in which we focus the evolution in the drug class of glucagon-like peptide 1 or glp-1 receptor agonist all of which require subcutaneous injection as you may know as the gel t1 receptor agonist have evolved administration schedules have become more convenient
In terms of dosing frequency for example doula glue tied rb glue tied and one of the formulations of exenatide are administered just once weekly several studies support a relationship between reduced dosing frequency greater preference from the patient’s perspective and improved adherence with guilty one receptor agonists another point is that advances in drug
Formulation may also increase adherence for example there are differences in reconstitution and preparation procedures prior to administration of note among the once-weekly glp-1 receptor agonist do the glue tied single dose prefilled pens are the only formulation with active drug already in solution and ready to use without the need for mixing or attaching a needle
Interestingly findings of a large observational study with a six-month follow-up period showed significantly better adherence and persistence with once weekly doula gu tied than wind once weekly eczema tied or once weekly laura gu tied moreover these conclusions are supported by data suggesting that patient reluctance to use injectable therapy may be overcome by
Use of a patient friendly delivery device in summary using evolution of the class of glp-1 receptor agonist as an example our review illustrates how advances in drug technology resulting in less frequent dosing and improved devices for drug administered can lead to better adherence and in turn may help to achieve better clinical outcomes
Transcribed from video
Adherence to antihyperglycemic medications and GLP1-RAs – Video Abstract ID 151736 By Dove Medical Press
